Fluorescent tamoxifen derivatives as biophotonic probes for the study of human breast cancer and estrogen-receptor directed photosensitizers

Currently, breast cancer is the most common type of cancer worldwide, being the so-called estrogen receptor (ER) positive the subtype with highest prevalence. For decades, the most successful strategy to prevent recurrence of ER + breast cancers is tamoxifen coadjuvant therapy. However, the involvement of the different estrogen receptors (ER alpha, ER beta and GPER) and the interaction in their signaling pathways, the evidence for sideeffects in chronic tamoxifen treatments, as well as the appearance of tamoxifen-resistant breast cancers, have encouraged the need for novel receptor-targeted fluorescent probes. In line with this, multifunctional antiestrogen conjugates, exhibiting fluorescent properties while retaining the ability to antagonize estrogen actions, have been synthesized and proven to be particularly useful in the study of the molecular biology of ER + breast cancers. These novel fluorescent tamoxifen derivatives (FTDs) exhibit pharmacological features of pure antiestrogens, with similar or even greater affinity for ER alpha than tamoxifen, inhibit ER-dependent gene transcription and cell proliferation, and are devoid of uterotrophic effects. In the present study we have aim at providing a detailed view of their biophotonic potential, including their spectroscopic properties, their usefulness for fluorescent labelling of cellular compartments and intracellular targets, their application in the identification of nonER antiestrogen binding sites thought fluorescence competition assays, and finally, in their ability to function as efficient ER-targeted photosensitizers.